VIALE-C

December 17, 2020December 17, 2020

Venclexta Combos Approved in Canada to Treat Newly Diagnosed AML

News

Health Canada has approved Venclexta (venetoclax) in combination with Vidaza (azacitidine) or low-dose cytarabine to treat newly diagnosed adults, ages 75 and older, with acute myeloid leukemia (AML), who have other ... Read more

October 22, 2020October 22, 2020

FDA Approves Venclexta Combinations for Newly Diagnosed AML

News

The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta (venetoclax), in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, for treating newly diagnosed adults with ... Read more

August 27, 2020August 27, 2020

Venclexta Plus Vidaza Increases AML Survival, Study Shows

News

Adding Venclexta (venetoclax) to treatment with Vidaza (azacitidine) significantly prolongs survival in people with acute myeloid leukemia (AML) who have not been treated before, a new study demonstrates. The study, ... Read more